Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:APHBCVE:NVHTSE:VSN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHBAmpliphi Biosciences$2.55+2.0%$0.00$0.15▼$1.37$85.35MN/A842,200 shs31,040 shsNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsVSNVeresenC$18.51C$11.40▼C$19.07C$5.81BN/A1.30 million shs1.15 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVHNovoheart0.00%0.00%0.00%0.00%0.00%VSNVeresen0.00%0.00%0.00%0.00%0.00%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AN/AN/AN/AVSNVeresenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHBAmpliphi BiosciencesN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AVSNVeresenN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/ANVHNovoheartC$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34VSNVeresenN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/ANVHNovoheartN/A-C$0.04N/A∞N/AN/AN/AN/AN/AVSNVeresenN/AN/A0.00N/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AVSNVeresenC$1.00N/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHBAmpliphi BiosciencesN/AN/AN/ANVHNovoheart27.626.136.05VSNVeresenN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHBAmpliphi BiosciencesN/ANVHNovoheartN/AVSNVeresenN/AInsider OwnershipCompanyInsider OwnershipAPHBAmpliphi BiosciencesN/ANVHNovoheartN/AVSNVeresenN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableNVHNovoheartN/A188.64 millionN/ANot OptionableVSNVeresen147,000314.00 millionN/ANot OptionableNVH, VSN, IMM, and APHB HeadlinesSourceHeadlineJordan Cove parent company looks at financing, ownership options, expansiontheworldlink.com - September 28 at 10:38 PMELD apologises after nearly 10,000 voters in Tanjong Pagar GRC receive two poll cards due to printer’s errorchannelnewsasia.com - August 27 at 8:05 AMJordan Cove donates more than $300,000 to defeat measuretheworldlink.com - May 22 at 9:08 AMEncuentran al menos 60 cadáveres en provincia del Congo - Chronnews.google.com - April 26 at 3:31 PMVeresen (TSE:VSN) Stock Price Passes Above Two Hundred Day ... - Defense Worldnews.google.com - April 18 at 8:35 AMOregon DEQ opens comments on permit renewal for former Weyerhaeuser facilitytheworldlink.com - April 11 at 5:09 PMBidders Can Structure Offers To Discourage The Use Of Rights Of ... - Mondaq News Alertsnews.google.com - April 5 at 8:22 AMRecuperan 36 cadáveres en un pozo tras derrumbe en India - Hartford City News Timesnews.google.com - March 31 at 10:30 PMThe Right Of First Refusal And Good Faith In Your Business Contract ... - Mondaq News Alertsnews.google.com - March 29 at 10:05 AMBidders can Structure Offers to Discourage the Use of Rights of First ... - Lexologynews.google.com - March 28 at 7:52 AMPembina Pipeline : Gas Infrastructure - Marketscreener.comnews.google.com - March 27 at 3:55 PMBidders can Structure Offers to Discourage the Use of Rights of First ... - McMillan LLPnews.google.com - March 27 at 3:55 PMBBC Sounds - Assignment - Available Episodesbbc.co.uk - March 25 at 8:34 PMThe Right of First Refusal and Good Faith in Your Business Contract ... - Lexologynews.google.com - March 21 at 3:02 PMLiquefied Natural Gas Market to See Massive Growth by 2029 ... - Digital Journalnews.google.com - March 14 at 7:23 PMNatural Gas Market Booming Worldwide( Forecast Period 2023-2029) With Top Player:BG Group plc, Apache Corporat - openPRnews.google.com - March 14 at 7:23 PMLong-term supply agreements and high inflation — what businesses ... - McCarthy Tétrault LLPnews.google.com - March 9 at 9:20 AMCEN: Reasonable CEF, But The Private Position Could Be A ... - Seeking Alphanews.google.com - March 8 at 5:49 PMInsights and Takeaways From Our Top 10 Commercial Litigation ... - Lexologynews.google.com - February 28 at 7:14 AMGlobal Natural Gas Market Industry Analysis, Size, Share, Demand ... - Taiwan Newsnews.google.com - February 27 at 9:13 PMHallan 18 cadáveres en Bulgaria; serían presuntos migrantes - Chronnews.google.com - February 17 at 3:48 PMMueren ahogadas 14 personas en accidente vial en México - Chronnews.google.com - February 8 at 11:35 PMCan A Bidder Structure An Offer To Discourage The Exercise Of A ... - Mondaqnews.google.com - February 8 at 6:35 PMMueren 14 en presunto accidente vial en norte de México - Chronnews.google.com - February 8 at 1:35 PMMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? All Headlines Company DescriptionsAmpliphi BiosciencesNYSEAMERICAN:APHBAmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.NovoheartCVE:NVHNovoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.VeresenTSE:VSNVeresen Inc is a Canada-based energy infrastructure company that owns and operates energy infrastructure assets across North America. The Company is engaged in three principal businesses: a pipeline transportation business consists of interests in the Alliance Pipeline, the Ruby Pipeline and the Alberta Ethane Gathering System (AEGS); a midstream business, which includes a partnership interest in Veresen Midstream Limited Partnership, which owns assets in western Canada, and an ownership interest in Aux Sable, which owns a natural gas liquids (NGL) extraction facility near Chicago, and other natural gas and NGL processing energy infrastructure, and a power business consists of a portfolio of assets in Canada. The Company's segments include Pipelines, Midstream, Power and Corporate. Alliance Pipeline owns and manages an integrated, high-pressure natural gas and NGL pipeline. Ruby Pipeline is a natural gas transmission system. AEGS is an integrated pipeline system. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.